Key result
In patients with cancer-associated acute venous thromboembolism, direct oral anticoagulants reduced the risk of recurrent VTE compared with dalteparin, without a higher likelihood of major bleeding.
Why the study?
Following the completion of a large trial comparing apixaban with dalteparin, an updated meta-analysis was needed to assess the efficacy and safety of DOACs versus LMWH in cancer-associated VTE.
Does the use of direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding in adult patients with cancer-associated acute VTE compared to low-molecular-weight heparin (LMWH)?
Meta-Analysis (n=2,894)
Does the use of direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding in adult patients with cancer-associated acute VTE compared to low-molecular-weight heparin (LMWH)?
In patients with cancer-associated VTE, DOACs are more effective than dalteparin for preventing recurrent VTE without a statistically significant increase in major bleeding, supporting their use as a preferred oral alternative.
Answers are grounded in this paper and cite their sources.
Supports DOAC preference over LMWH for cancer-associated VTE; reinforces Level 1 evidence from aggregated trials.
Background International guidelines have endorsed the use of edoxaban or rivaroxaban as an alternative to low-molecular-weight heparin (LMWH) for the treatment of acute venous thromboembolism (VTE) in cancer patients. Recently, a large randomized controlled trial of apixaban versus dalteparin in patients with cancer was completed. We performed an updated meta-analysis to assess the efficacy and safety of direct oral anticoagulants (DOACs) versus LMWH in patients with cancer-associated VTE. Methods MEDLINE, EMBASE, and CENTRAL (Cochrane Controlled Trials Registry) were systematically searched up to March 30, 2020 for randomized controlled trials comparing DOACs versus LMWH for the treatment of VTE in patients with cancer. The two coprimary outcomes were recurrent VTE and major bleeding at 6 months. Data were pooled by the Mantel–Haenszel method and compared by relative risk ratios (RRs) and 95% confidence intervals (CIs). Results Four randomized controlled studies (2,894 patients) comparing apixaban, edoxaban, or rivaroxaban with dalteparin were included in the meta-analysis. Recurrent VTE occurred in 75 of 1,446 patients (5.2%) treated with oral factor Xa inhibitors and in 119 of 1,448 patients (8.2%) treated with LMWH (RR 0.62; 95% CI 0.43–0.91; I 2, 30%). Major bleeding occurred in 62 (4.3%) and 48 (3.3%) patients receiving oral factor Xa inhibitors or LMWH, respectively (RR 1.31; 95% CI 0.83–2.08; I 2, 23%). Conclusion In patients with cancer-associated VTE, oral factor Xa inhibitors reduced the risk of recurrent VTE without a significantly higher likelihood of major bleeding at 6 months compared with LMWH.
No takes yet. Share an insight, caveat, or question.
Giustozzi et al. (2020) conducted a meta-analysis in Acute venous thromboembolism associated with cancer (n=2,894). Direct Oral Anticoagulants (apixaban, edoxaban, or rivaroxaban) vs. Low-molecular-weight heparin (dalteparin) was evaluated on Recurrent VTE at 6 months (RR 0.62, 95% CI 0.43-0.91). In patients with cancer-associated acute venous thromboembolism, direct oral anticoagulants reduced the risk of recurrent VTE compared with dalteparin, without a higher likelihood of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: